[2]Bruce B Allan1,Stacie Bell2,Kathryn Husarek2.A 12-month feasibility study to investigate the effectiveness of cryogen-cooled monopolar radiofrequency treatment for female stress urinary incontinence.Can Urol Assoc J. 2020 Jul;14(7):E313-E318. doi: 10.5489/cuaj.6145. [3]Shelena Lalji1,P...
Viveve gets CE mark for vaginal treatmentThe article reports that the Viveve system for the non-surgical treatment of laxity of the vaginal opening after childbirth from Viveve has received the European CE manda...
In conclusion, Mr. Durbin stated, 'Pending positive PURSUIT trial results in mid-2022 and subsequent FDA approval, our non-invasive SUI treatment has the potential to treat an estimated 25-30 million women in the U.S. who suffer from SUI.' 2020 and Recent Business Highlight...
VIVE: Viveve Medical, Inc. Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal ...+ VIEW MORE ...
Vos JA, Livengood RH, Jessop M, Coad JE. Non-ablative hyperthermic mesenchymal regeneration: a proposed mechanism of action based on the Viveve model. In: Ryan TP, editor. Energy-Based Treatment of Tissue and Assessment VI. Vol. 7901. Bellingham, WA: Proc SPIE; 2011; pp. 1...
027 VIVEVE I: VIveve Treatment of the Vaginal Introitus to Evaluate Effectiveness: An Interim Analysisdoi:10.1016/j.jsxm.2016.04.027Krychman, M.L.Wilkerson, D.Elsevier Inc.Journal of Sexual Medicine
Viveve Obtains CE Mark For Gynecologic Treatment Of Vaginal LaxityAnna Ohlden
VIVE: Viveve Medical, Inc. Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal ...+ VIEW MORE ...